GlycoMira is developing an effective treatment for chronic rhinosinusitis, a debilitating inflammatory disease that substantially diminishes the quality of life and productivity of up to 16% of the U.S. population and requires $64B annually in direct costs to treat patients. Currently available therapies fail to help 20% of patients, underscoring the dire need for new therapeutics that can improve the lives of millions of Americans.
NIH Grant Awards
GlycoMira received Small Business Innovation Research grant awards.
Kummarapurugu AB, Zheng S, Pulsipher A, Savage JR, et al (2021) Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum. American Journal of Respiratory Cell and Molecular Biology. 64(2):260-267. https://doi: 10.1165/rcmb.2020-0157OC
Alt JA, Lee WY, Davis BM, Savage JR, Kennedy TP, Prestwich GD, et al. (2018) A synthetic glycosaminoglycan reduces sinonasal inflammation in a murine model of chronic rhinosinusitis. PLoS ONE 13(9): e0204709. https://doi.org/10.1371/journal.pone.0204709